Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chinese Patent Office
Covington
UBS
US Department of Justice
Queensland Health
Daiichi Sankyo
Dow
Johnson and Johnson
Fuji

Generated: October 17, 2017

DrugPatentWatch Database Preview

TIAGABINE HYDROCHLORIDE - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tiagabine hydrochloride and what is the scope of tiagabine hydrochloride patent protection?

Tiagabine hydrochloride
is the generic ingredient in two branded drugs marketed by Cephalon and Sun Pharm Inds, and is included in two NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tiagabine hydrochloride has twenty-five patent family members in twenty-one countries and two supplementary protection certificates in two countries.

There are five drug master file entries for tiagabine hydrochloride. Seven suppliers are listed for this compound.

Summary for Generic Name: TIAGABINE HYDROCHLORIDE

US Patents:1
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: see list5
Suppliers / Packagers: see list7
Bulk Api Vendors: see list35
Clinical Trials: see list2,301
Patent Applications: see list523
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:TIAGABINE HYDROCHLORIDE at DailyMed

Pharmacology for Ingredient: TIAGABINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-006Nov 29, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-001Sep 30, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-003Sep 30, 1997RXYesNo► Subscribe► Subscribe ► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-002Sep 30, 1997RXYesNo► Subscribe► Subscribe ► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-004Sep 30, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-005Apr 16, 1999ABRXYesNo► Subscribe► Subscribe ► Subscribe
Sun Pharm Inds
TIAGABINE HYDROCHLORIDE
tiagabine hydrochloride
TABLET;ORAL077555-002Nov 4, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-008Nov 29, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm Inds
TIAGABINE HYDROCHLORIDE
tiagabine hydrochloride
TABLET;ORAL077555-001Nov 4, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-007Nov 29, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: tiagabine hydrochloride

International Patent Family for Ingredient: tiagabine hydrochloride

Country Document Number Estimated Expiration
Norway316889► Subscribe
Spain2181002► Subscribe
Czech Republic9804019► Subscribe
Australia3165397► Subscribe
Israel127469► Subscribe
Australia723267► Subscribe
Japan2000511909► Subscribe
Argentina008236► Subscribe
Poland330424► Subscribe
South Africa9705266► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TIAGABINE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0107Belgium► SubscribePRODUCT NAME: TIAGABINE CHLORHYDRATE MONOHYDRATE - TIAGABINE ANHYDRE; NAT. REGISTRATION NO/DATE: 403 IS 102 F 3 19970602; FIRST REGISTRATION: FR 341 260.2 19960614
C/GB98/022United Kingdom► SubscribePRODUCT NAME: TIAGABINE ( INCLUDING SALTS THEREOF ); REGISTERED: FR AMM NO. 341 260.2 19960614; FR AMM NO. 341 262.5 19960614; FR AMM NO. 341 264.8 19960614; UK 03132/0117 19971111; UK 03132/0118 19971111; UK 03132/0119 19971111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Chinese Patent Office
Colorcon
Daiichi Sankyo
Chubb
Mallinckrodt
Teva
Medtronic
Cerilliant
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot